Mohammed Dhiyaa Almusawi
Biomedical Engineering Graduate from Swinburne University of Technology | Eager to develop medical innovations to evolve health care and quality of life
Universal Biosensors Inc (UBI) is a global biosensor company and a world leader in electrochemical cell technology. UBI’s ambition is to utilize its patented biosensor technology to develop a diverse range of biosensor test strips used in our hand-held portable analyzers; for cost effective, effortless, and accurate detection of analytes of interest, within many industries including human health, animal health, environmental, and agriculture. UBI is a USA Delaware company listed on the Australian Securities Exchange (ASX:UBI) and operates from its head office, manufacturing facility, and research laboratory in Melbourne, Victoria, Australia. In 2021, UBI successfully launched its unique handheld wine analyzer called Sentia™ with an initial test to measure free SO2 , and subsequently in 2022, tests for monitoring malic acid and glucose throughout the wine production process (more tests in the pipeline are due for release in late 2022). In 2022, UBI launched Xprecia Prime™ in the EU and UK, the next-generation blood coagulation analyzer which replaces Xprecia Stride™. Xprecia Prime™ is due for launch in the US in 2023. UBI is due to launch Petrackr™ in late 2022/early 2023, a veterinary blood glucometer to monitor diabetes in cats and dogs. These products will complement UBI’s existing Canadian blood testing laboratory Hemostasis Reference Lab (HRL).
